A detailed history of Macquarie Group LTD transactions in Avita Medical, Inc. stock. As of the latest transaction made, Macquarie Group LTD holds 864 shares of RCEL stock, worth $10,324. This represents 0.0% of its overall portfolio holdings.

Number of Shares
864
Previous 4,301 79.91%
Holding current value
$10,324
Previous $34,000 73.53%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$7.72 - $10.87 $26,533 - $37,360
-3,437 Reduced 79.91%
864 $9,000
Q2 2024

Aug 09, 2024

BUY
$7.92 - $15.55 $26,278 - $51,594
3,318 Added 337.54%
4,301 $34,000
Q1 2024

May 14, 2024

BUY
$12.56 - $18.31 $653 - $952
52 Added 5.59%
983 $15,000
Q4 2023

Feb 14, 2024

SELL
$9.29 - $14.57 $8,453 - $13,258
-910 Reduced 49.43%
931 $12,000
Q3 2023

Nov 14, 2023

SELL
$13.84 - $20.79 $22,074 - $33,160
-1,595 Reduced 46.42%
1,841 $26,000
Q2 2023

Aug 14, 2023

SELL
$10.7 - $17.48 $9,544 - $15,592
-892 Reduced 20.61%
3,436 $58,000
Q1 2023

May 15, 2023

BUY
$6.45 - $14.48 $27,915 - $62,669
4,328 New
4,328 $60,000
Q1 2022

May 16, 2022

SELL
$6.96 - $12.15 $182,184 - $318,038
-26,176 Closed
0 $0
Q4 2021

Feb 11, 2022

SELL
$11.72 - $19.66 $66,804 - $112,062
-5,700 Reduced 17.88%
26,176 $314,000
Q3 2021

Nov 12, 2021

BUY
$16.73 - $20.9 $382,313 - $477,606
22,852 Added 253.24%
31,876 $565,000
Q2 2021

Aug 13, 2021

BUY
$17.23 - $22.02 $145,559 - $186,024
8,448 Added 1466.67%
9,024 $185,000
Q1 2021

May 14, 2021

SELL
$18.38 - $28.41 $152,645 - $235,945
-8,305 Reduced 93.51%
576 $11,000
Q4 2020

Feb 16, 2021

SELL
$17.55 - $27.2 $59,775 - $92,643
-3,406 Reduced 27.72%
8,881 $165,000
Q3 2020

Nov 13, 2020

BUY
$20.83 - $30.0 $255,938 - $368,610
12,287 New
12,287 $375,000

Others Institutions Holding RCEL

About AVITA Medical, Inc.


  • Ticker RCEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 25,030,900
  • Market Cap $299M
  • Description
  • AVITA Medical Inc. operates as a commercial-stage regenerative tissue company in the United States, Australia, and the United Kingdom. It offers regenerative products to address unmet medical needs in burn injuries, trauma injuries, chronic wounds, and dermatological and aesthetics indications, including vitiligo. The company's patented and prop...
More about RCEL
Track This Portfolio

Track Macquarie Group LTD Portfolio

Follow Macquarie Group LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Macquarie Group LTD, based on Form 13F filings with the SEC.

News

Stay updated on Macquarie Group LTD with notifications on news.